Rearrangement of Coordinate Selection for Triangle Features Improvement in Digit Recognition

Triangle geometry feature demonstrated as useful properties in classifying the image. This feature has been implemented in numerous recognition field such as biometric area, security area, medical area, geological area, inspection area and digit recognition area. This study is focusing on improving triangle features in digit recognition. Commonly, triangle features are explored by determining three points of triangle shape which represent as A, B and C to extract useful features in digit recognition. There is possibilities triangle shape cannot be formed when chosen coordinate are in line. Thus, a prior study has proposed an improvement on triangle selection point technique by determining the position of coordinate A, B and C use gradient value to identify the triangle shape can be modelled or vice versa. The suggested improvement is based on the dominant distribution which only covers certain areas of an image. Hence, a method named Triangle Point using Three Block (Tp3B) was proposed in this study. The proposed method proposes the arrangement of selection coordinate point based on three different blocks which where all coordinates points of an image were covered. Experiments have developed over image digit dataset of IFCHDB, HODA, MNIST and BANGLA which contains testing and train data of each. Features classification accuracy tested using supervised machine learning (SML) which is Support Vector Machine (SVM). Experimental results show, the proposed technique gives a promising result for dataset HODA and MNIST

Land Used Mapping using Unmanned Aerial Vehicle (UAV) along Parit Rasipan Drainage System

Excess nutrients accelerate the growth of plants and algae in water sources, leading to environmental issues like flow retardation (flood), a decrease in the amount of oxygen in the water, and a decline in the quality of the water. Therefore, the goal of this study is to identify the quality Parit Rasipan drainage system's eutrophic level in terms of temperature, dissolved oxygen, pH, and turbidity; and to analyse an NDVI (Normalized Difference Vegetation Index) image taken by unmanned aerial vehicle (UAV) and using Agisoft photoscan software. As a result, four sampling locations—residential (S1), industrial (S2), agricultural (S3), and farming (S4)—have been chosen for water quality sampling and analysis along the Parit Rasipan drainage system. The HACH method was used to analyse water samples that have been obtained according to the Standard Methods for Water and Wastewater Examinations. It was found that agricultural zone was poor water quality compared residential, industrial and farming zones with measurements of 3.82 mg/L, 3.09, 25.57 °C, and 14.6 NTU, respectively, the agricultural zone has the highest values for the four metrics of dissolved oxygen, pH, temperature, and turbidity. This scenario could be due to the usage of the fertilizer to cultivate the oil palm contributed to Parit rasipan drainage system (S3) which resulted in a substantial amount of eutrophication. Hence, the use of UAVs and the agisoft photoscan programme has considerably improved the mapping of the water quality metrics and eutrophic level

Pelatihan Pengelolaan Keuangan Berbasis Teknologi Informasi Bagi UMKM di Desa Margodadi

Kecepatan dan ketepatan adaptasi para pelaku usaha mikro kecil menengah untuk bersaing, salah satunya ditentukan oleh ditentukan oleh kemampuan pemanfaatan teknologi dalam proses produksi, distribusi, pemasaran, maupun pengelolaan keuangan. Margodadi merupakan salah satu desa di Kecamatan Ambarawa, Kabupaten Pringsewu, Lampung memiliki kurang lebih seratus UMKM yang tercatat di Dinas Koperasi dan UMKM Kabupaten Pringsewu. Menyadari pentingnya pengelolaan keuangan parktis menggunakan aplikasi berbasis android, maka tim pengabdian STMIK Pringsewu mengadakan pelatihan untuk membantu warga khususnya pelaku usaha mikro kecil menengah untuk mengenal, mengetahui, dan menggunakan manfaat penggunaan pengelolaan keuangan berbasis teknologi informasi dalam sistem pembukuan debit kredit. Kegiatan ini bertujuan untuk memperkenalkan aplikasi pembukuan cash flow bagi para pelaku usaha di Desa Margodadi. Pelatihan ini berfokus pada keuangan, sehingga pelaku usaha akan diberikan penjelasan mengenai cara mengelola pendapatan, menggunakan media ataupun aplikasi gratis yang mendukung. Metode yang digunakan dalam aktivitas pengabdian ini meliputi ceramah, demo, dan diskusi untuk memantapkan pengetahuan peserta UMKM. Melalui kuisioner yang diberikan kepada peserta, dari 92% peserta yang telah memiliki usaha, 76% di antaranya tertarik menggunakan aplikasi pengelolaan keuangan “Bukukas”

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

Background: The EMPA KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. Methods: EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. Findings: Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5–2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62–0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16–1·59), representing a 50% (42–58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1). Interpretation: In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. Funding: Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council

Drug-eluting coating of ginsenoside Rg1 and Re incorporated poly(lactic-co-glycolic acid) on stainless steel 316L: physicochemical and drug release analyses

Active ingredients of ginsenoside, Rg1 and Re, are able to inhibit the proliferation of vascular smooth muscle cells and promote the growth of vascular endothelial cells. These capabilities are of interest for developing a novel drug-eluting stent to potentially solve the current problem of late-stent thrombosis and poor endotheliazation. Therefore, this study was aimed to incorporate ginsenoside into degradable coating of poly(lactic-co-glycolic acid) (PLGA). Drug mixture composed of ginseng extract and 10% to 50% of PLGA (xPLGA/g) was coated on electropolished stainless steel 316L substrate by using a dip coating technique. The coating was characterized principally by using attenuated total reflectance-Fourier transform infrared spectroscopy, scanning electron microscopy and contact angle analysis, while the drug release profile of ginsenosides Rg1 and Re was determined by using mass spectrometry at a one month immersion period. Full and homogenous coating coverage with acceptable wettability was found on the 30PLGA/g specimen. All specimens underwent initial burst release dependent on their composition. The 30PLGA/g and 50PLGA/g specimens demonstrated a controlled drug release profile having a combination of diffusion- and swelling-controlled mechanisms of PLGA. The study suggests that the 30PLGA/g coated specimen expresses an optimum composition which is seen as practicable for developing a controlled release drug-eluting stent

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

Background: The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. Methods: EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. Findings: Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5-2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62-0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16-1·59), representing a 50% (42-58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1). Interpretation: In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. Funding: Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council